Veterinary Medicines

Global Veterinary Medicines Market to Reach ## by 2030

The global market for Veterinary Medicines estimated at ## in the year 2024, is expected to reach ## by 2030, growing at a CAGR of 0.0% over the analysis period 2024-2030.

Global Veterinary Medicine Market – Key Trends & Drivers Summarized

Is Veterinary Medicine Becoming the Linchpin of Modern Animal Healthcare?
Veterinary medicine has evolved far beyond its traditional role of animal treatment and care, now emerging as a critical pillar supporting public health, food security, and even biomedical innovation. The global veterinary medicine market is undergoing a dynamic transformation driven by advances in diagnostics, therapeutics, and precision animal health. With increasing awareness around zoonotic diseases—where pathogens jump from animals to humans—governments and international agencies are reinforcing surveillance and control mechanisms. This has pushed investments in veterinary healthcare infrastructure and sparked a surge in demand for both preventive and therapeutic veterinary drugs. Moreover, livestock health has taken on strategic economic significance, as the quality and yield of animal-based products such as milk, meat, and eggs are directly linked to effective veterinary care. The rising prevalence of infectious diseases like avian influenza, African swine fever, and foot-and-mouth disease has led to significant losses in the global animal agriculture sector, further emphasizing the criticality of veterinary interventions. Simultaneously, pet humanization has become a global trend, with pet owners willing to spend more on advanced treatment and nutritional supplements, driving growth in the companion animal segment. Regulatory agencies like the FDA, EMA, and USDA are also accelerating drug approvals and improving regulatory clarity, further boosting R&D outcomes in the sector. In addition, there is increasing convergence between veterinary and human medicine, particularly in the One Health approach that links animal, human, and environmental health within a shared ecosystem of diagnostics, surveillance, and epidemiology.

How Is Innovation in Veterinary Pharmaceuticals and Biologics Transforming the Market Landscape?
A wave of innovation is reshaping veterinary medicine, especially within the pharmaceutical and biologics sectors. Pharmaceutical advancements are increasingly mimicking human medical breakthroughs, with the development of long-acting injectables, controlled-release drug delivery systems, and novel antimicrobial agents tailored to species-specific pharmacokinetics. Biologics, particularly vaccines and monoclonal antibodies, are experiencing explosive growth. DNA-based and vector-based vaccines are under rapid development, offering better immunogenic profiles and longer-lasting immunity with minimal side effects. Autogenous vaccines are gaining traction, especially in swine and poultry industries, enabling tailored protection based on farm-specific pathogen strains. Moreover, antiparasitic innovations have emerged in response to rising resistance among parasites to traditional anthelmintics and ectoparasiticides. Companies are increasingly utilizing AI and machine learning to analyze massive veterinary datasets to design targeted therapies and optimize clinical outcomes. Nutraceuticals and probiotic formulations have also gained popularity, driven by the rise in organic livestock farming and pet wellness. Further, regulatory pathways are evolving to accommodate innovative delivery platforms such as transdermal patches and oral suspensions with improved palatability for companion animals. Major players like Zoetis, Elanco, Boehringer Ingelheim, and Merck Animal Health are doubling down on R&D and strategic acquisitions to secure novel therapeutics and capture wider market share. This biopharmaceutical boom is also aided by the emergence of dedicated veterinary CROs (Contract Research Organizations), which are expediting clinical trials and commercial rollouts. The differentiation between biologics and small molecules in terms of pricing, patent dynamics, and administration protocols is adding new layers of complexity and opportunity to the global veterinary medicine market.

What Role Do Digital Technologies and Advanced Diagnostics Play in Shaping Veterinary Practice?
The infusion of digital technologies and advanced diagnostics into veterinary medicine has fundamentally altered how animal health is monitored, diagnosed, and managed. Wearable devices for livestock and pets are now capable of capturing vital biometric data in real time—such as body temperature, movement patterns, feeding behavior, and calving cycles—enabling early detection of illness and behavioral anomalies. Precision livestock farming, powered by IoT-enabled sensors and cloud computing, is fostering more efficient herd management and reducing disease transmission. Veterinary telemedicine, once a niche service, has gained mainstream acceptance post-COVID-19, allowing veterinarians to consult remotely, prescribe treatments, and monitor chronic conditions without physical visits. This has been particularly impactful in remote or underserved rural areas. Molecular diagnostics, including RT-PCR, ELISA, and next-generation sequencing (NGS), are rapidly replacing traditional microbiological techniques due to their speed, sensitivity, and specificity. These tools are proving invaluable in identifying emerging zoonotic threats and tailoring individualized treatment plans. Lab-on-a-chip devices are making point-of-care diagnostics feasible, even for small clinics and mobile veterinary units. Integration of veterinary electronic health records (EHRs) with analytics dashboards is offering clinicians data-driven insights, helping streamline case management, treatment efficacy tracking, and drug usage auditing. Cloud-based practice management software is further automating administrative tasks such as inventory, billing, and patient tracking. As a result, veterinary practices are becoming smarter, more responsive, and increasingly proactive, aligning well with the growing expectations of animal owners and food producers alike. Additionally, artificial intelligence is enabling image recognition tools for radiology and histopathology, improving diagnostic accuracy while reducing interpretation timeframes. These digital enablers are playing a pivotal role in not just improving outcomes but also expanding access to quality veterinary care worldwide.

The Growth In The Global Veterinary Medicine Market Is Driven By Several Factors…
The upward trajectory of the veterinary medicine market is underpinned by a multitude of well-defined, market-specific drivers spanning technological, demographic, regulatory, and end-user domains. A primary catalyst is the intensifying demand for protein-rich diets globally, which is increasing livestock populations and creating heightened pressure to maintain optimal animal health for food safety and yield. Companion animal ownership is also witnessing a boom, especially in urban and high-income demographics, leading to increased expenditure on preventive care, wellness supplements, and advanced veterinary procedures. On the technology front, the adoption of advanced diagnostic platforms and automated monitoring systems has significantly improved disease surveillance and early intervention outcomes. Innovations in vaccine technology, including mRNA-based and vector-based platforms, have enabled rapid immunization against endemic and emerging diseases. The widespread emergence of antimicrobial resistance (AMR) in both humans and animals is compelling the development of next-generation antimicrobials and stewardship programs, further pushing drug innovation. Shifts in regulatory frameworks, particularly streamlined approval processes in North America and Europe, are enabling faster time-to-market for novel therapeutics. Agribusinesses are increasingly integrating veterinary services within supply chains to reduce mortality and improve product traceability, spurring demand for services and health management tools. The globalization of livestock trade, along with international food safety norms, has elevated the importance of disease-free certification and veterinary oversight. Moreover, the rise of corporate veterinary chains and animal hospitals is formalizing care delivery models, enabling economies of scale and enhanced service delivery. Pet insurance uptake is also rising steadily, especially in developed economies, making costly treatments more accessible and further encouraging the adoption of premium veterinary services. All these interconnected developments—rooted in shifting consumer behaviors, innovation pipelines, industry consolidation, and policy reform—are creating a powerful ecosystem conducive to sustained growth in the global veterinary medicine market.

SCOPE OF STUDY:

The report analyzes the Veterinary Medicines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Animal Type (Production Animals, Companion Animals); Product (Biologics, Pharmaceuticals, Medicated Feed Additives); Administration Route (Oral, Injectable, Topical, Other Routes); Distribution Channel (Veterinary Hospitals & Clinics, E-Commerce, Offline Retail Stores, Others)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

• Bayer Animal Health
• Bimeda
• Boehringer Ingelheim
• Ceva Santé Animale
• Chanelle Pharma Group
• Dechra Pharmaceuticals PLC
• Eco Animal Health
• Elanco
• Heska Corporation
• IDEXX Laboratories, Inc.
• Indian Immunologicals Ltd.
• KRKA
• Merck Animal Health
• National Veterinary Associates
• Neogen Corporation
• Norbrook Laboratories
• Orion Pharma
• Phibro Animal Health Corporation
• Vetoquinol S.A.
• Virbac

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.